Worldwide, colorectal carcinoma ranks as the third most common cancer, following lung and breast cancers, according to the Global Cancer Observatory (IARC-WHO, 2022). Screening typically involves non-invasive fecal-based tests or direct visualization via colonoscopy, with the choice guided by individual risk factors, patient frailty, comorbidities, and cost considerations. Dietary and lifestyle modifications, as well as managing comorbidities such as uncontrolled type 2 diabetes mellitus and obesity, can help reduce the risk of colorectal cancer. Clinical symptoms often emerge only in the later stages of the disease, underscoring the need for a high index of suspicion and early referral in patients with subtle signs. Colonoscopy remains the gold standard for diagnosis, and should be followed by appropriate staging investigations. Treatment is guided by standardized histopathology reports using the AJCC Tumor-Node-Metastasis (TNM) staging system, with interventions including surgical resection, chemotherapy, and radiotherapy. Post-treatment monitoring involves tracking serum carcinoembryonic antigen (CEA) levels, performing surveillance colonoscopy, and conducting relevant imaging studies.